重性抑郁障碍在发作期与缓解期存在持续分子病理
该研究对四个MDD队列(单次发作、单次发作缓解、反复发作、反复发作缓解)及一个对照队列的膝下前扣带回皮层死后样本进行质谱蛋白质组学分析(3630种蛋白)。结果显示,无论当前处于发作还是缓解状态、无论既往发作次数,MDD均存在持续的蛋白质组学改变,涉及突触前神经传递、突触功能、细胞骨架重排、能量代谢、磷脂生物合成/代谢和钙离子稳态,但未发现可检测的进行性神经病理。
要点
- MDD患者膝下前扣带回皮层存在持续蛋白质组学改变,不随发作或缓解状态消失。
- 改变涉及突触前神经传递、突触功能、能量代谢、磷脂代谢和钙稳态等通路。
- 未发现与发作次数或当前状态相关的进行性神经病理证据。
核心结论
- 重性抑郁障碍在发作期和缓解期均存在持续的分子病理改变,但未检测到进行性神经病理。
研究设计与样本
- 分析四个MDD队列(单次发作n=20、单次发作缓解n=15、反复发作n=20、反复发作缓解n=15)及一个对照队列(n=20)的膝下前扣带回皮层死后样本。
- 采用基于质谱的蛋白质组学检测3630种蛋白,并结合统计分析和假设检验评估状态与特质性神经病理。
主要发现
- 数据仅提供弱证据支持蛋白质组差异随抑郁/缓解状态或既往发作次数变化。
- 无论发作或缓解状态,MDD均存在持续的蛋白质组学改变,涉及突触前神经传递、突触功能、细胞骨架重排、能量代谢、磷脂生物合成/代谢和钙离子稳态。
- 二氢嘧啶酶相关蛋白1、突触体相关蛋白29、谷氨酸脱羧酶1、代谢型谷氨酸受体1和兴奋性氨基酸转运体3经Western blot验证。
- 上述发现独立于技术、人口学(性别或年龄)或其他临床参数(自杀死亡和药物治疗)。
临床怎么用
- 提示MDD的分子病理可能持续存在于缓解期,支持将缓解期视为需要持续关注生物学异常的阶段。
- 涉及的突触传递、能量代谢和钙稳态等通路可为未来治疗靶点探索提供线索。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder (MDD) is a debilitating mental illness and a major cause of lost productivity worldwide. MDD patients often suffer from lifelong recurring episodes of increasing severity, reduced therapeutic response, and shorter remission periods, suggesting the presence of a persistent and potentially progressive pathology. METHODS: Subgenual anterior cingulate cortex postmortem samples from four MDD cohorts (single episode, n = 20; single episode in remission, n = 15; recurrent episode, n = 20; and recurrent episode in remission, n = 15), and one control cohort (n = 20) were analyzed by mass spectrometry-based proteomics (n = 3630 proteins) combined with statistical analyses. The data was investigated for trait and state progressive neuropathologies in MDD using both unbiased approaches and tests of a priori hypotheses. RESULTS: The data provided weak evidence for proteomic differences as a function of state (depressed/remitted) or number of previous episodes. Instead it suggested the presence of persistent MDD effects, regardless of episodes or remitted state, namely on proteomic measures related to presynaptic neurotransmission, synaptic function, cytoskeletal rearrangements, energy metabolism, phospholipid biosynthesis/metabolism, and calcium ion homeostasis. Selected proteins (dihydropyrimidinase-related protein 1, synaptosomal-associated protein 29, glutamate decarboxylase 1, metabotropic glutamate receptor 1, and excitatory amino acid transporter 3) were validated by Western blot analysis. The findings were independent of technical, demographic (sex or age), or other clinical parameters (death by suicide and drug treatment). CONCLUSIONS: Collectively, the results provide evidence for persistent MDD effects across current episodes or remission, in the absence of detectable progressive neuropathology.
引用
- Scifo E, Pabba M, Kapadia F, et al. Sustained Molecular Pathology Across Episodes and Remission in Major Depressive Disorder. Biol Psychiatry. 2017. PMID: 28935211. doi:10.1016/j.biopsych.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。